Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

The committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’s Prevnar 20 to 50 years down from 65.

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

In a 15-0 vote, ACIP recommended that MenB-4C be administered as a two-dose series at 0 and 6 months when given to healthy ...

Pfizer's strong success in developing a covid-19 vaccine and treatment yielded a ... related to product governance ESG risks, such as off-label marketing or litigation related to side effects.

Pfizer's dividend is expected to grow slowly ... the 200% sales spike from COVID-19 vaccines, that will never be repeated. If you exclude the 2023 earnings collapse (-73%), the median growth ...

RSV vaccine sales by GSK and Pfizer have dropped in the U.S. after regulators limited the eligible age group, affecting ...